EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis

Sarah E Stansfield iD, Jesse Heitner, Kate M Mitchell iD, Carla M Doyle iD, Rachael M Milwid, Mia Moore, Deborah J Donnell, Brett Hanscom, Yiqing Xia, Mathieu Maheu-Giroux iD, David van de Vijver iD, Haoyi Wang iD und 3 weitere

Journal of the International AIDS Society · 2023

DOI: 10.1002/jia2.26109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2023. Verfasst von Sarah E Stansfield und 14 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: HIV Infections, Sexual and Gender Minorities, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) in the HPTN 083/084 trials. We compared the potential impact of expanding PrEP coverage by offering CAB‐LA to men who have sex with men (MSM) in Atlanta (US), Montreal (Canada) and the Netherlands, settings with different HIV epidemics.

Methods

Three risk‐stratified HIV transmission models were independently parameterized and calibrated to local data. In Atlanta, Montreal and the Netherlands, the models, respectively, estimated mean TDF/FTC coverage starting at 29%, 7% and 4% in 2022, and projected HIV incidence per 100 person‐years (PY), respectively, decreasing from 2.06 to 1.62, 0.08 to 0.03 and 0.07 to 0.001 by 2042. Expansion of PrEP coverage was simulated by recruiting new CAB‐LA users and by switching different proportions of TDF/FTC users to CAB‐LA. Population effectiveness and efficiency of PrEP expansions were evaluated over 20 years in comparison to baseline scenarios with TDF/FTC only.

Results

Increasing PrEP coverage by 11 percentage points (pp) from 29% to 40% by 2032 was expected to avert a median 36% of new HIV acquisitions in Atlanta. Substantially larger increases (by 33 or 26 pp) in PrEP coverage (to 40% or 30%) were needed to achieve comparable reductions in Montreal and the Netherlands, respectively. A median 17 additional PYs on PrEP were needed to prevent one acquisition in Atlanta with 40% PrEP coverage, compared to 1000+ in Montreal and 4000+ in the Netherlands. Reaching 50% PrEP coverage by 2032 by recruiting CAB‐LA users among PrEP‐eligible MSM could avert >45% of new HIV acquisitions in all settings. Achieving targeted coverage 5 years earlier increased the impact by 5–10 pp. In the Atlanta model, PrEP expansions achieving 40% and 50% coverage reduced differences in PrEP access between PrEP‐indicated White and Black MSM from 23 to 9 pp and 4 pp, respectively.

Conclusions

Achieving high PrEP coverage by offering CAB‐LA can impact the HIV epidemic substantially if rolled out without delays. These PrEP expansions may be efficient in settings with high HIV incidence (like Atlanta) but not in settings with low HIV incidence (like Montreal and the Netherlands).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsSexual and Gender MinoritiesPre-Exposure ProphylaxisHumansMaleBlack PeopleCanadaEmtricitabineHomosexuality, MaleTenofovirWhiteGeorgiaNetherlandsBlack or African AmericanPyridonesDiketopiperazines

Stichwörter der Autor:innen

EuropeHIV preventionNorth AmericaPrEPmen who have sex with menmodelling

Substanzen

EmtricitabineTenofovircabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK.
  • Department of Nursing and Community Health, Glasgow Caledonian University London, London, UK.
  • MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
  • Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, Québec, Canada.

ORCID-Profile: Sarah E Stansfield, Kate M Mitchell, Carla M Doyle, Mathieu Maheu-Giroux, David van de Vijver, Haoyi Wang

Förderung

  • Medical Research Council
  • NIAID NIH HHS

Zitieren

APA

Stansfield, S. E., Heitner, J., Mitchell, K. M., Doyle, C. M., Milwid, R. M., Moore, M., Donnell, D. J., Hanscom, B., Xia, Y., Maheu-Giroux, M., Vijver, D. V., Wang, H., Barnabas, R., Boily, M. C., & Dimitrov, D. T. (2023). Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26109

Vancouver

Stansfield SE, Heitner J, Mitchell KM, Doyle CM, Milwid RM, Moore M, et al. Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis. Journal of the International AIDS Society. 2023. doi:10.1002/jia2.26109

BibTeX
@article{Stansfield2023,
  author = {Stansfield, Sarah E and Heitner, Jesse and Mitchell, Kate M and Doyle, Carla M and Milwid, Rachael M and Moore, Mia and Donnell, Deborah J and Hanscom, Brett and Xia, Yiqing and Maheu-Giroux, Mathieu and Vijver, David van de and Wang, Haoyi and Barnabas, Ruanne and Boily, Marie-Claude and Dimitrov, Dobromir T},
  title = {Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis},
  journal = {Journal of the International AIDS Society},
  year = {2023},
  doi = {10.1002/jia2.26109}
}
Kostenlos starten →